Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Catridecacog - NovoNordisk

Next Previous
X
Search
Drug Profile

Catridecacog - NovoNordisk

Alternative Names: NN-1810; NN-1841; NN8717; NovoThirteen; Recombinant factor XIII - Novo Nordisk; Recombinant human factor XIII - Novo Nordisk; rFXIII - Novo Nordisk; rhFactor-XIII - Novo Nordisk; rhFXIII - Novo Nordisk; Tretten

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ZymoGenetics
  • Developer Novo Nordisk
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Factor XIII deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Factor XIII deficiency
  • No development reported Postpartum haemorrhage; Ulcerative colitis

Most Recent Events

  • 23 Jul 2020 CHMP recommends approval of catridecacog for Factor XIII deficiency on extension of existing indication of
  • 07 Nov 2018 Launched for Factor XIII deficiency (In children, In adults) in Norway (IV)
  • 07 Nov 2018 Launched for Factor XIII deficiency (In children, In infants) in Norway (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top